Yann Wallez

Publication Activity (10 Years)

Years Active: 2018-2022
Publications (10 Years): 3

Top Topics

Randomized Controlled Trial

Radiation Therapy

Locally Advanced

Top Venues

Cancer research

Clinical cancer research : an official journal of the American Association for Cancer Research

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Krista Kinneer, Philipp Wortmann, Zachary A Cooper, Niall J Dickinson, Luke A Masterson, Thais Cailleau, Ian Hutchinson, Balakumar Vijayakrishnan, Mary McFarlane, Kathryn Ball, Michael Davies, Arthur Lewis, Yue Huang, Anton I Rosenbaum, Jiaqi Yuan, Jon Chesebrough, Judith Anderton, Noel Monks, Steven J Novick, Jixin Wang, Nazzareno Dimasi, R James Christie, Darrin Sabol, Frances Anne Tosto, Yann Wallez, Elisabetta Leo, Mark R Albertella, Anna D Staniszewska, David A Tice, Philip W Howard, Nadia Luheshi, Puja Sapra
Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Zena Wilson, Rajesh Odedra, Yann Wallez, Paul W G Wijnhoven, Adina M Hughes, Joe Gerrard, Gemma N Jones, Hannah Bargh-Dawson, Elaine Brown, Lucy A Young, Lenka Oplustil O'Connor, Alan Lau
ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib. Cancer research 82 (6) (2022)
Yann Wallez, Charles R Dunlop, Timothy Isaac Johnson, Siang-Boon Koh, Chiara Fornari, James W T Yates, Sandra Bernaldo de Quirós Fernández, Alan Lau, Frances M Richards, Duncan I Jodrell
The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression. Molecular cancer therapeutics 17 (8) (2018)